[Form 4] Marker Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Marker Therapeutics, Inc. (MRKR) reported that director Norman David Eansor received new stock option awards. On 11/17/2025, he was granted options to purchase 84,411 shares of common stock at an exercise price of $0.9548 per share under the company’s 2020 Omnibus Stock Ownership Plan, representing the remaining options for his service as a director for 2024. These options vest on the anniversary of the grant date and expire on 11/17/2035.

On the same date, he was also granted options to purchase an additional 137,330 shares of common stock at an exercise price of $0.9548 per share for his service as a director for 2025. These options have the same vesting schedule and expiration date of 11/17/2035 and are held as direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eansor Norman David

(Last) (First) (Middle)

C/O MARKER THERAPEUTICS, INC.

2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Marker Therapeutics, Inc. [ MRKR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.9548	11/17/2025		A		84,411		(1)	11/17/2035	Common Stock	84,411	$0	84,411	D
Stock Option (Right to Buy)	$0.9548	11/17/2025		A		137,330		(2)	11/17/2035	Common Stock	137,330	$0	137,330	D

Explanation of Responses:

1. Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.

2. Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.

	/s/ Julio C. Esquivel as Attorney-In-Fact for Norman David Eansor	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Marker Therapeutics (MRKR) disclose in this Form 4?

The filing reports that director Norman David Eansor received two stock option grants under Marker Therapeutics’ 2020 Omnibus Stock Ownership Plan on 11/17/2025 for his board service in 2024 and 2025.

How many stock options did Norman David Eansor receive from MRKR on November 17, 2025?

He received options to buy 84,411 shares of common stock for remaining 2024 director service and options to buy 137,330 shares for 2025 director service, all at an exercise price of $0.9548 per share.

What is the exercise price and expiration date of the MRKR options granted to the director?

Both option grants to Norman David Eansor have an exercise price of $0.9548 per share, based on the closing price on November 17, 2025, and they expire on 11/17/2035.

When do Norman David Eansor’s Marker Therapeutics options vest?

The options granted for both the 2024 and 2025 director service vest on the anniversary of the grant date, which is November 17 following the grant.

Are the MRKR stock options held directly or indirectly by the reporting person?

The Form 4 shows that the options to purchase 84,411 and 137,330 shares of Marker Therapeutics common stock are held with direct (D) ownership by Norman David Eansor.

Under which plan were the Marker Therapeutics options to Norman David Eansor granted?

Both sets of options were granted under Marker Therapeutics’ 2020 Omnibus Stock Ownership Plan as compensation for his service as a director for the years 2024 and 2025.